###begin article-title 0
Glomerular angiotensinogen protein is enhanced in pediatric IgA nephropathy
###end article-title 0
###begin p 1
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 1076 1081 <span type="species:ncbi:9606">human</span>
Enhanced intrarenal renin-angiotensin system (RAS) is implicated in the development and progression of renal injury. To investigate whether angiotensinogen (AGT) expression is involved in glomerular RAS activity and glomerular injury, we examined glomerular AGT expression and its correlation with expression of other RAS components, and levels of glomerular injury in samples from patients with immunoglobulin A nephropathy (IgAN) (23) and minor glomerular abnormalities (MGA) (8). Immunohistochemistry showed that AGT protein was highly expressed by glomerular endothelial cells (GEC) and mesangial cells in nephritic glomeruli of IgAN compared with glomeruli of MGA. Levels of glomerular AGT protein were well correlated with levels of glomerular angiotensin II (ang II), transforming growth factor-beta (TGF-beta), alpha-smooth-muscle actin, glomerular cell number, and glomerulosclerosis score but not with those of glomerular angiotensin-converting enzyme and ang II type 1 receptor. Real-time polymerase chain reaction (RT-PCR) and Western blot analyses using cultured human GEC indicated that ang II upregulated AGT messenger ribonucleic acid (mRNA) and protein expression in a dose- and time-dependent manner. These data suggest that activated glomerular AGT expression is likely involved in elevated local ang II production and, thereby, may contribute to increased TGF-beta production and development of glomerular injury in IgAN. Augmentation of GEC-AGT production with ang II stimulation might drive further glomerular injury in a positive-feedback loop.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 552 553 552 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 843 844 843 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 845 847 845 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 758 762 <span type="species:ncbi:10116">rats</span>
###xml 767 773 <span type="species:ncbi:9606">humans</span>
Clinical and experimental studies have provided considerable evidence for the role of the renin-angiotensin system (RAS) in the development of hypertension and progression of renal diseases [1, 2]. It is now established that all components of the RAS are widely distributed in several tissues, including the kidney [3, 4]. The local RAS in the kidney has several pathophysiologic functions for not only regulating blood pressure but also renal cell growth and production of glomerulosclerosis, which is involved in the development of renal fibrosis [5-8]. Indeed, previous studies have shown beneficial effects of angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II (ang II) type 1 receptor (AT1R) blocker (ARB) on various renal diseases in rats and humans, often to an extent far greater than their effect on blood pressure [9-11].
###end p 4
###begin p 5
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 207 209 207 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 715 717 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1462 1464 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1612 1614 1606 1608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 1615 1617 1609 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 588 596 <span type="species:ncbi:9606">patients</span>
###xml 1584 1587 <span type="species:ncbi:10116">rat</span>
IgA nephropathy (IgAN) is now recognized to be the most common form of glomerulonephritis worldwide. It has been reported that more than 30% of cases progress to end-stage renal failure within 20 years [12, 13]. In pediatric IgAN, glomerular lesion is characterized by an increased number of mesangial cells (MC) and accumulation of mesangial extracellular matrix (ECM), and this pathological change is thought to be an early and active lesion for IgAN [14]. It is reported that treatment with ACEi and/or ARB provides antiproteinuric and renoprotective effects in normotensive pediatric patients with IgAN, suggesting that intrarenal action of ang II may play a critical role in the progression of pediatric IgAN [15, 16]. Recently, a real-time polymerase chain reaction (RT-PCR) study using isolated glomeruli with IgAN revealed an increased expression of RAS components such as renin, angiotensinogen (AGT), and ACE, possibly followed by the production of ang II, an effector molecule of RAS, suggesting that the glomerular RAS activation might occur under this disease setting [17]. In this study, AGT messenger ribonucleic acid (mRNA) levels were positively correlated with the mRNA expression of renin, ACE, and a fibrogenic cytokine transforming growth factor-beta (TGF-beta). AGT is the sole substrate for the RAS pathway, and it has been reported that AGT is present within the kidney and ang II is produced locally, independent of the circulating RAS [18]. Interestingly, the increased expression of intrarenal AGT is directly involved in the disease progression in several rat models of renal injury [19-22]. However, little information is available about protein expression in an RAS cascade from AGT to ang II and the association between glomerular RAS activation and pathological changes in childhood IgAN.
###end p 5
###begin p 6
###xml 449 454 <span type="species:ncbi:9606">human</span>
Therefore, in this study, the glomerular protein expression of RAS components such as AGT, ACE, ang II, and AT1R, as well as their association with the index of glomerular injury were examined to clarify the role of the RAS cascade, especially that of AGT in glomerular lesions of pediatric IgAN. Subsequently, we investigated the amplification mechanism of glomerular AGT expression leading to an increase of glomerular RAS activity using cultured human glomerular endothelial cells (GEC).
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
Kidney tissue
###end title 8
###begin p 9
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 2160 2162 2160 2162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 2202 2203 2202 2203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 2205 2212 2205 2212 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 2212 2237 2212 2237 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="10">Clinical data of patients</p>
###xml 2212 2237 2212 2237 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="10">Clinical data of patients</p></caption>
###xml 2237 2238 2237 2238 <th xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</th>
###xml 2238 2241 2238 2241 <th xmlns:xlink="http://www.w3.org/1999/xlink">MGA</th>
###xml 2241 2245 2241 2245 <th xmlns:xlink="http://www.w3.org/1999/xlink">IgAN</th>
###xml 2237 2245 2237 2245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>&#160;</th><th>MGA</th><th>IgAN</th></tr>
###xml 2237 2245 2237 2245 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th>&#160;</th><th>MGA</th><th>IgAN</th></tr></thead>
###xml 2245 2251 2245 2251 <td xmlns:xlink="http://www.w3.org/1999/xlink">Number</td>
###xml 2251 2252 2251 2252 <td xmlns:xlink="http://www.w3.org/1999/xlink">8</td>
###xml 2252 2254 2252 2254 <td xmlns:xlink="http://www.w3.org/1999/xlink">23</td>
###xml 2245 2254 2245 2254 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Number</td><td>8</td><td>23</td></tr>
###xml 2254 2265 2254 2265 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)</td>
###xml 2265 2277 2265 2275 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.1&#8201;&#177;&#8201;1.9</td>
###xml 2277 2289 2275 2285 <td xmlns:xlink="http://www.w3.org/1999/xlink">13.0&#8201;&#177;&#8201;3.1</td>
###xml 2254 2289 2254 2285 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)</td><td>13.1&#8201;&#177;&#8201;1.9</td><td>13.0&#8201;&#177;&#8201;3.1</td></tr>
###xml 2289 2353 2285 2349 <td xmlns:xlink="http://www.w3.org/1999/xlink">Term from onset of urinary abnormalities to renal biopsy (years)</td>
###xml 2353 2364 2349 2358 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.5&#8201;&#177;&#8201;1.2</td>
###xml 2364 2375 2358 2367 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9&#8201;&#177;&#8201;0.7</td>
###xml 2289 2375 2285 2367 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Term from onset of urinary abnormalities to renal biopsy (years)</td><td>1.5&#8201;&#177;&#8201;1.2</td><td>0.9&#8201;&#177;&#8201;0.7</td></tr>
###xml 2375 2415 2367 2407 <td xmlns:xlink="http://www.w3.org/1999/xlink">Systolic/diastolic blood pressure (mmHg)</td>
###xml 2415 2441 2407 2429 <td xmlns:xlink="http://www.w3.org/1999/xlink">112.1&#8201;&#177;&#8201;9.5/62.6&#8201;&#177;&#8201;7.5</td>
###xml 2441 2468 2429 2452 <td xmlns:xlink="http://www.w3.org/1999/xlink">111.0&#8201;&#177;&#8201;10.4/61.3&#8201;&#177;&#8201;7.9</td>
###xml 2375 2468 2367 2452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Systolic/diastolic blood pressure (mmHg)</td><td>112.1&#8201;&#177;&#8201;9.5/62.6&#8201;&#177;&#8201;7.5</td><td>111.0&#8201;&#177;&#8201;10.4/61.3&#8201;&#177;&#8201;7.9</td></tr>
###xml 2468 2487 2452 2471 <td xmlns:xlink="http://www.w3.org/1999/xlink">Proteinuria (g/day)</td>
###xml 2487 2500 2471 2482 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.07&#8201;&#177;&#8201;0.04</td>
###xml 2500 2514 2482 2494 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.37&#8201;&#177;&#8201;0.26*</td>
###xml 2468 2514 2452 2494 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Proteinuria (g/day)</td><td>0.07&#8201;&#177;&#8201;0.04</td><td>0.37&#8201;&#177;&#8201;0.26*</td></tr>
###xml 2514 2529 2494 2509 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hematuria index</td>
###xml 2529 2542 2509 2520 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.93&#8201;&#177;&#8201;0.37</td>
###xml 2542 2556 2520 2532 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.89&#8201;&#177;&#8201;0.70*</td>
###xml 2514 2556 2494 2532 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hematuria index</td><td>0.93&#8201;&#177;&#8201;0.37</td><td>1.89&#8201;&#177;&#8201;0.70*</td></tr>
###xml 2556 2578 2532 2554 <td xmlns:xlink="http://www.w3.org/1999/xlink">Serum creatine (mg/dl)</td>
###xml 2578 2591 2554 2565 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.54&#8201;&#177;&#8201;0.14</td>
###xml 2591 2604 2565 2576 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.54&#8201;&#177;&#8201;0.15</td>
###xml 2556 2604 2532 2576 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Serum creatine (mg/dl)</td><td>0.54&#8201;&#177;&#8201;0.14</td><td>0.54&#8201;&#177;&#8201;0.15</td></tr>
###xml 2646 2647 2618 2619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2604 2648 2576 2620 <td xmlns:xlink="http://www.w3.org/1999/xlink">24-h creatine clearance (ml/min per 1.73&#160;m<sup>2</sup>)</td>
###xml 2648 2662 2620 2632 <td xmlns:xlink="http://www.w3.org/1999/xlink">100.5&#8201;&#177;&#8201;23.5</td>
###xml 2662 2676 2632 2644 <td xmlns:xlink="http://www.w3.org/1999/xlink">103.8&#8201;&#177;&#8201;29.9</td>
###xml 2604 2676 2576 2644 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>24-h creatine clearance (ml/min per 1.73&#160;m<sup>2</sup>)</td><td>100.5&#8201;&#177;&#8201;23.5</td><td>103.8&#8201;&#177;&#8201;29.9</td></tr>
###xml 2245 2676 2245 2644 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Number</td><td>8</td><td>23</td></tr><tr><td>Age (years)</td><td>13.1&#8201;&#177;&#8201;1.9</td><td>13.0&#8201;&#177;&#8201;3.1</td></tr><tr><td>Term from onset of urinary abnormalities to renal biopsy (years)</td><td>1.5&#8201;&#177;&#8201;1.2</td><td>0.9&#8201;&#177;&#8201;0.7</td></tr><tr><td>Systolic/diastolic blood pressure (mmHg)</td><td>112.1&#8201;&#177;&#8201;9.5/62.6&#8201;&#177;&#8201;7.5</td><td>111.0&#8201;&#177;&#8201;10.4/61.3&#8201;&#177;&#8201;7.9</td></tr><tr><td>Proteinuria (g/day)</td><td>0.07&#8201;&#177;&#8201;0.04</td><td>0.37&#8201;&#177;&#8201;0.26*</td></tr><tr><td>Hematuria index</td><td>0.93&#8201;&#177;&#8201;0.37</td><td>1.89&#8201;&#177;&#8201;0.70*</td></tr><tr><td>Serum creatine (mg/dl)</td><td>0.54&#8201;&#177;&#8201;0.14</td><td>0.54&#8201;&#177;&#8201;0.15</td></tr><tr><td>24-h creatine clearance (ml/min per 1.73&#160;m<sup>2</sup>)</td><td>100.5&#8201;&#177;&#8201;23.5</td><td>103.8&#8201;&#177;&#8201;29.9</td></tr></tbody>
###xml 2237 2676 2237 2644 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>MGA</th><th>IgAN</th></tr></thead><tbody><tr><td>Number</td><td>8</td><td>23</td></tr><tr><td>Age (years)</td><td>13.1&#8201;&#177;&#8201;1.9</td><td>13.0&#8201;&#177;&#8201;3.1</td></tr><tr><td>Term from onset of urinary abnormalities to renal biopsy (years)</td><td>1.5&#8201;&#177;&#8201;1.2</td><td>0.9&#8201;&#177;&#8201;0.7</td></tr><tr><td>Systolic/diastolic blood pressure (mmHg)</td><td>112.1&#8201;&#177;&#8201;9.5/62.6&#8201;&#177;&#8201;7.5</td><td>111.0&#8201;&#177;&#8201;10.4/61.3&#8201;&#177;&#8201;7.9</td></tr><tr><td>Proteinuria (g/day)</td><td>0.07&#8201;&#177;&#8201;0.04</td><td>0.37&#8201;&#177;&#8201;0.26*</td></tr><tr><td>Hematuria index</td><td>0.93&#8201;&#177;&#8201;0.37</td><td>1.89&#8201;&#177;&#8201;0.70*</td></tr><tr><td>Serum creatine (mg/dl)</td><td>0.54&#8201;&#177;&#8201;0.14</td><td>0.54&#8201;&#177;&#8201;0.15</td></tr><tr><td>24-h creatine clearance (ml/min per 1.73&#160;m<sup>2</sup>)</td><td>100.5&#8201;&#177;&#8201;23.5</td><td>103.8&#8201;&#177;&#8201;29.9</td></tr></tbody></table>
###xml 2676 2679 2644 2647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGA</italic>
###xml 2711 2716 2679 2684 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> IgAN</italic>
###xml 2676 2745 2644 2713 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11"><italic>MGA</italic> minor glomerular abnormalities,<italic> IgAN</italic> immunoglobulin A nephropathy</p>
###xml 2745 2782 2713 2748 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12">Data are means &#177; standard deviation</p>
###xml 2783 2785 2749 2751 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2782 2799 2748 2765 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="13">*<italic> P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p>
###xml 2676 2799 2644 2765 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11"><italic>MGA</italic> minor glomerular abnormalities,<italic> IgAN</italic> immunoglobulin A nephropathy</p><p textid="12">Data are means &#177; standard deviation</p><p textid="13">*<italic> P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></table-wrap-foot>
###xml 2205 2799 2205 2765 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="10">Clinical data of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>&#160;</th><th>MGA</th><th>IgAN</th></tr></thead><tbody><tr><td>Number</td><td>8</td><td>23</td></tr><tr><td>Age (years)</td><td>13.1&#8201;&#177;&#8201;1.9</td><td>13.0&#8201;&#177;&#8201;3.1</td></tr><tr><td>Term from onset of urinary abnormalities to renal biopsy (years)</td><td>1.5&#8201;&#177;&#8201;1.2</td><td>0.9&#8201;&#177;&#8201;0.7</td></tr><tr><td>Systolic/diastolic blood pressure (mmHg)</td><td>112.1&#8201;&#177;&#8201;9.5/62.6&#8201;&#177;&#8201;7.5</td><td>111.0&#8201;&#177;&#8201;10.4/61.3&#8201;&#177;&#8201;7.9</td></tr><tr><td>Proteinuria (g/day)</td><td>0.07&#8201;&#177;&#8201;0.04</td><td>0.37&#8201;&#177;&#8201;0.26*</td></tr><tr><td>Hematuria index</td><td>0.93&#8201;&#177;&#8201;0.37</td><td>1.89&#8201;&#177;&#8201;0.70*</td></tr><tr><td>Serum creatine (mg/dl)</td><td>0.54&#8201;&#177;&#8201;0.14</td><td>0.54&#8201;&#177;&#8201;0.15</td></tr><tr><td>24-h creatine clearance (ml/min per 1.73&#160;m<sup>2</sup>)</td><td>100.5&#8201;&#177;&#8201;23.5</td><td>103.8&#8201;&#177;&#8201;29.9</td></tr></tbody></table><table-wrap-foot><p textid="11"><italic>MGA</italic> minor glomerular abnormalities,<italic> IgAN</italic> immunoglobulin A nephropathy</p><p textid="12">Data are means &#177; standard deviation</p><p textid="13">*<italic> P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></table-wrap-foot></table-wrap>
###xml 56 64 <span type="species:ncbi:9606">children</span>
###xml 745 753 <span type="species:ncbi:9606">Patients</span>
###xml 856 864 <span type="species:ncbi:9606">Patients</span>
###xml 1327 1339 <span type="species:ncbi:9606">participants</span>
###xml 1363 1371 <span type="species:ncbi:9606">Patients</span>
###xml 1633 1641 <span type="species:ncbi:9606">patients</span>
###xml 2229 2237 <span type="species:ncbi:9606">patients</span>
Renal tissues used for this study were obtained from 23 children with IgAN and eight with minor glomerular abnormalities (MGA) by biopsy. Diagnosis of renal diseases was made based on studies of tissue by light, electron, and immunofluorescence microscopy according to the classification of the World Health Organization (WHO) [23]. This classification defined diffuse mesangial proliferation as >80% of glomeruli showing moderate or severe mesangial cell proliferation, i.e. more than three cells per peripheral mesangial area, and focal mesangial proliferation as up to 80% of glomeruli showing the same changes described above. IgAN was diagnosed as a mesangial proliferative glomerulonephritis with predominant IgA deposit in the mesangium. Patients diagnosed with IgAN showed diffuse mesangial proliferation (15) or focal mesangial proliferation (8). Patients diagnosed with MGA showed normal glomerular morphology and negative immunofluorescence but had mild proteinuria or microscopic hematuria. All subjects with other disorders, including Henoch-Schonlein purpura, systemic lupus erythematosus, and chronic liver disease, were excluded. The control tissue (5) consisted of normal cortex taken from kidneys resected for localized neoplasms. Blood pressure, serum creatinine, and creatinine clearance were normal in all participants at the time of biopsy. Patients had not been previously treated with either ACEi, ARB, glucocorticosteroids, or immunosuppressive agents. The study protocol was approved by the ethics committee of the University of Tokushima Graduate School, and written informed consent was obtained from all patients and/or their parents in all cases. The clinical laboratory parameters, including age, term from onset of urinary abnormalities to renal biopsy, blood pressure, proteinuria, hematuria index, serum creatinine, and 24-h creatinine clearance were determined at the time of biopsy. Based on examination of urine samples, the severity of hematuria was classified as follows: 0, 0-5 erythrocytes/high-power field (HPF); 1+, 5-30 erythrocytes/HPF; 2+, >30 erythrocytes/HPF; 3+, macroscopic hematuria, as previously described [24]. Clinical data are presented in Table 1. Table 1Clinical data of patients MGAIgANNumber823Age (years)13.1 +/- 1.913.0 +/- 3.1Term from onset of urinary abnormalities to renal biopsy (years)1.5 +/- 1.20.9 +/- 0.7Systolic/diastolic blood pressure (mmHg)112.1 +/- 9.5/62.6 +/- 7.5111.0 +/- 10.4/61.3 +/- 7.9Proteinuria (g/day)0.07 +/- 0.040.37 +/- 0.26*Hematuria index0.93 +/- 0.371.89 +/- 0.70*Serum creatine (mg/dl)0.54 +/- 0.140.54 +/- 0.1524-h creatine clearance (ml/min per 1.73 m2)100.5 +/- 23.5103.8 +/- 29.9MGA minor glomerular abnormalities, IgAN immunoglobulin A nephropathyData are means +/- standard deviation* P < 0.01 vs MGA
###end p 9
###begin p 10
###xml 17 25 <span type="species:ncbi:9606">patients</span>
Clinical data of patients
###end p 10
###begin p 11
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MGA</italic>
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> IgAN</italic>
MGA minor glomerular abnormalities, IgAN immunoglobulin A nephropathy
###end p 11
###begin p 12
Data are means +/- standard deviation
###end p 12
###begin p 13
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
* P < 0.01 vs MGA
###end p 13
###begin title 14
Histological scoring of glomerular cell proliferation, glomerulosclerosis, and tubulointerstitial changes
###end title 14
###begin p 15
###xml 490 492 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 601 603 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 814 816 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 977 979 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
For light-microscopic examination, the biopsied tissues were fixed in 10% buffered formalin and embedded in paraffin. Paraffin sections (3 mum) were stained with periodic acid-Schiff reagent. All glomeruli in each section (usually 10-26) were coded and read by a blinded observer. The number of cells in at least four equatorially cut glomeruli in each section was counted, and the average number of cells was used as an indicator of glomerular cell proliferation, as previously described [25]. The glomerulosclerosis (GS) score was determined using a previously described method with a modification [26]. The percentage of each glomerulus occupied by mesangial ECM was estimated and assigned a code as follows: 0, absent; 1+, 1-5%; 2+, 5-25%; 3+, 25-50%; 4+, >50%; and the mean value per specimen was calculated [27]. To evaluate the level of tubulointerstitial change, three to five fields of the cortical interstitium in each section were examined, as previously described [28]. In each field, tubulointerstitial change, like tubular atrophy and interstitial broadening, were graded as follows: 0, representing involvement of <5%; 1+, involvement between 5 and 20%; 2+, involvement between 20 and 40%; 3+, involvement of >40%.
###end p 15
###begin title 16
Antibodies
###end title 16
###begin p 17
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 0 7 <span type="species:ncbi:9031">Chicken</span>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 139 144 <span type="species:ncbi:10090">Mouse</span>
###xml 175 181 <span type="species:ncbi:9986">rabbit</span>
###xml 216 222 <span type="species:ncbi:9986">rabbit</span>
###xml 420 425 <span type="species:ncbi:10090">Mouse</span>
###xml 581 586 <span type="species:ncbi:9606">human</span>
###xml 591 597 <span type="species:ncbi:9986">Rabbit</span>
Chicken IgY-rich fraction against highly purified full-length human plasma AGT (anti-AGT antibody) was used for immunohistochemistry [29]. Mouse monoclonal anti-ACE antibody, rabbit polyclonal anti-ang II serum, and rabbit polyclonal anti-AT1R antibody were purchased from Chemicon International (Temecula, CA, USA), IgG corporation (Nashville, TN, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. Mouse monoclonal anti-alpha-smooth-muscle (alpha-SM) actin antibody (1A4) was purchased from Sigma-Aldrich (St. Louis, MO, USA) and was used to detect activated human MC. Rabbit polyclonal anti-TGF-beta antibody was a kind gift from Dr. Kawachi (Niigata University, Niigata, Japan).
###end p 17
###begin title 18
Immunohistochemistry
###end title 18
###begin p 19
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 288 295 <span type="species:ncbi:9031">chicken</span>
###xml 366 372 <span type="species:ncbi:9986">rabbit</span>
The glomerular expression of AGT or AT1R was detected by an immunoperoxidase technique, as previously described [27]. Briefly, the sections (3 mum) were incubated with the primary antibodies overnight at 4degreesC. After rinsing, the sections were incubated with either biotinylated anti-chicken IgG (for AGT) (Vector Labs, Burlingame, CA, USA) or biotinylated anti-rabbit IgG (for AT1R) (Vector Labs). After rinsing, the sections were incubated with avidin-biotin-peroxidase complex (ABC Elite; Vector Labs), followed by 3,3'-diaminobenzidine (Dojindo, Kumamoto, Japan). Each section was counterstained with Mayer's hematoxylin (Wako, Tokyo, Japan), dehydrated, and coverslipped.
###end p 19
###begin p 20
###xml 1669 1671 1657 1659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 2089 2091 2070 2072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 67 74 <span type="species:ncbi:9031">chicken</span>
###xml 140 146 <span type="species:ncbi:9793">donkey</span>
###xml 152 159 <span type="species:ncbi:9031">chicken</span>
###xml 267 272 <span type="species:ncbi:10090">mouse</span>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 375 380 <span type="species:ncbi:10090">mouse</span>
###xml 541 547 <span type="species:ncbi:9793">donkey</span>
###xml 553 558 <span type="species:ncbi:10090">mouse</span>
###xml 811 817 <span type="species:ncbi:9793">donkey</span>
###xml 823 829 <span type="species:ncbi:9986">rabbit</span>
###xml 844 850 <span type="species:ncbi:9793">donkey</span>
###xml 856 861 <span type="species:ncbi:10090">mouse</span>
###xml 885 891 <span type="species:ncbi:9793">donkey</span>
###xml 897 902 <span type="species:ncbi:10090">mouse</span>
In double-staining experiments, 3-mum frozen sections stained with chicken anti-AGT antibody, and fluorescein-isothiocyanate (FITC)-labeled donkey anti-chicken IgG antibody (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) were further incubated with either mouse anti-CD31 antibody (DAKO, Glostrup, Denmark), mouse monoclonal anti-alpha-SM actin antibody (1A4), or mouse monoclonal synaptopodin antibody (G1D4; Progen Biotechnik, Heidelberg, Germany), followed by an appropriate tetramethylrhodamine-isothiocyanate (TRITC)-coupled donkey anti-mouse antibody (Jackson Immuno-Research Laboratories). Indirect immunofluorescent staining was performed using the following primary antibodies: anti-ACE antibody, anti-ang II antiserum, anti-alpha-SM actin antibody, and anti-TGF-beta antibody. FITC-labeled donkey anti-rabbit IgG antibody, donkey anti-mouse IgG, and TRITC-labeled donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories) were used as the secondary antibodies. Frozen sections were incubated with primary antibodies for 1 h, and then secondary antibodies, appropriately. To evaluate the level of glomerular staining with each antibody, we performed semiquantitative analysis. The immunostaining of AGT was graded as follows: 0, very weak or absent capillary or mesangial staining; 1+, weak capillary staining with 1-25% focally increased capillary staining; 2+, 25-50% of glomerular tuft demonstrating strong capillary and mesangial staining; 3+, 50-75% of glomerular tuft demonstrating strong capillary and mesangial staining; 4+, 75% or more of the glomerular tuft demonstrated strong capillary and mesangial staining, as previously described [25]. The immunostaining of ACE, ang II, AT1R, TGF-beta, and alpha-SM actin was graded as follows: 0, no staining; 1+, weak staining; 2+, mild staining; 3+, moderate staining; 4+, marked staining. At least four equatorially sectioned glomeruli in each section were evaluated blindly by two separate investigators. The individual immunostaining score was determined by calculating the average value per single glomerulus [27].
###end p 20
###begin title 21
Cell culture
###end title 21
###begin p 22
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 437 440 437 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 444 446 444 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;9</sup>
###xml 450 452 450 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 677 679 677 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 106 111 <span type="species:ncbi:9606">Human</span>
###xml 206 211 <span type="species:ncbi:9606">Human</span>
Cultured human GEC derived from normal human kidneys were purchased from Cell System (Kirkland, WA, USA). Human GEC were cultured on culture flask coated with type 1 collagen, as described previously [30]. Human GEC were used at the sixth to eighth passage in our experiments. At about 70-80% confluency, GEC growth was arrested by incubation for 48 h in serum-free medium and then treated with ang II at increasing concentrations (0, 10-11, 10-9, 10-7 M) for 3-12 h to detect mRNA or protein, respectively. In addition, a time-course study was undertaken to assess changes in AGT mRNA expression at 0, 1, 3, 6, 12, and 24 h and protein expression at 0, 6, 12, and 24 h with 10-7 M ang II-treated GEC. Cells were harvested for RNA extraction and total cell extract preparation.
###end p 22
###begin title 23
Western blot
###end title 23
###begin p 24
###xml 930 932 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 376 387 <span type="species:ncbi:3704">horseradish</span>
###xml 410 416 <span type="species:ncbi:9986">rabbit</span>
###xml 422 429 <span type="species:ncbi:9031">chicken</span>
###xml 430 436 <span type="species:ncbi:9103">turkey</span>
###xml 807 812 <span type="species:ncbi:9606">human</span>
Human GEC cultures were dissolved in radioimmunoprecipitation assay (RIPA) buffer. Protein samples (25 mug) were separated by 12.5% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes (Amersham Bioscience, Piscataway, NJ, USA). The membranes were probed with anti-AGT antibody (1:1,000) and then incubated with a horseradish peroxidase-conjugated rabbit anti-chicken/turkey IgG (H+L) (1:2,000; Zymed Laboratories, San Francisco, CA, USA). Equivalent protein loading for each lane was confirmed by stripping and reblotting each membrane for beta-actin (1:10,000; Sigma-Aldrich). Immunoreactive proteins were detected with an enhanced chemiluminescence detection system (Amersham Corp., Arlington Heights, IL, USA). The antibodies were tested on human purified AGT (Calbiochem, Merck, Darmstadt, Germany) as control, where two bands between 50 and 60 kD were detected [31]. Bands were quantitated by ImageJ 1.33u (National Institute of Health), and the fold expression was indicated as the relative protein level.
###end p 24
###begin title 25
RT-PCR
###end title 25
###begin p 26
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 758 764 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> G3PDH</italic>
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
Total RNA (500 ng) extracted from human cell cultures was reverse transcripted using the SYBR ExScript RT-PCR Kit (TaKaRa, Kyoto, Japan). The complementary DNAs (cDNAs) were amplified by RT-PCR with primers for human AGT (forward 5'-TCTCCCCGGACCATCCA-3' and reverse 5'-TGCTCAATTTTTGCAGGTTCAG-3') and glyceraldehyde-3 phosphate dehydrogenase (G3PDH) (forward 5'-GAAGGTGAAGGTCGGAGT-3' and reverse 5'-TGGCAACAATATCCACTTTACCA-3') as an internal control, using iCycler Thermal Cycler (BioRad, Hercules, CA, USA) [17, 32]. Melting curve analysis and PAGE confirmed the specificity of the amplification products. Semiquantification data were analyzed with iCycler analysis software and expressed as the ratio between starting the quantity mean of the target and the G3PDH gene.
###end p 26
###begin title 27
Statistical analysis
###end title 27
###begin p 28
###xml 176 177 174 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 492 494 490 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> t</italic>
###xml 510 512 508 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
Results are presented as means +/- standard deviation (SD). StatView (SAS institute) was used for statistical analyses. Between-group differences were assessed by the unpaired t test. The correlation of two variations was evaluated using Pearson's or Spearman's correlation coefficients. Western blot and RT-PCR analyses were performed at least three times, and representative results are shown in the figures. The mRNA expression or protein synthesis of AGT in cultured cells was analyzed by t test. Values of P < 0.05 were considered statistically significant.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Clinical data and histologic changes in patients
###end title 30
###begin p 31
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 375 376 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 538 539 538 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 705 707 705 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 744 746 744 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1007 1009 1007 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1020 1026 1020 1026 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1066 1067 1066 1067 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1090 1091 1090 1091 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1126 1127 1126 1127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1362 1363 1357 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1385 1386 1375 1376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1026 1400 1026 1390 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="32">The scorings of glomerular cell number (<bold>a</bold>), glomerulosclerosis (<bold>b</bold>), and tubulointerstitial changes (<bold>c</bold>) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (&#9632;) compared with minor glomerular abnormalities (MGA) (&#9633;). *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs MGA; &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p>
###xml 1026 1400 1026 1390 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="32">The scorings of glomerular cell number (<bold>a</bold>), glomerulosclerosis (<bold>b</bold>), and tubulointerstitial changes (<bold>c</bold>) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (&#9632;) compared with minor glomerular abnormalities (MGA) (&#9633;). *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs MGA; &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></caption>
###xml 1400 1400 1390 1390 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig1_HTML" id="MO1"/>
###xml 1020 1400 1020 1390 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="32">The scorings of glomerular cell number (<bold>a</bold>), glomerulosclerosis (<bold>b</bold>), and tubulointerstitial changes (<bold>c</bold>) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (&#9632;) compared with minor glomerular abnormalities (MGA) (&#9633;). *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs MGA; &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig1_HTML" id="MO1"/></fig>
###xml 17 25 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 339 347 <span type="species:ncbi:9606">patients</span>
###xml 365 373 <span type="species:ncbi:9606">patients</span>
###xml 501 508 <span type="species:ncbi:9606">patient</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 651 659 <span type="species:ncbi:9606">patients</span>
###xml 829 837 <span type="species:ncbi:9606">patients</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
Clinical data in patients with MGA or IgAN are listed in Table 1. There were no significant differences between MGA and IgAN patients for age, follow-up term from onset of urinary abnormalities, blood pressure, serum creatinine, and creatinine clearance at the time of biopsy. Mean urine protein excretion was significantly higher in IgAN patients than that in MGA patients (P < 0.01). The extent of glomerular cellularity, ECM accumulation, and tubulointerstitial changes were semiquantified in both patient groups and are shown in Fig. 1. The glomerular cell number and GS score were significantly higher in IgAN patients compared with those in MGA patients (MGA vs IgAN; mean cell number: 66.1 vs 77.9, P < 0.05; mean GS score: 0.73 vs 1.58, P < 0.01). Tubular atrophy and interstitial broadening were faintly present in IgAN patients but not in MGA patients. However, there was no significant difference in tubulointerstitial score change between the two groups (mean score: 0.00 in MGA vs 0.26 in IgAN, P = 0.188). Fig. 1The scorings of glomerular cell number (a), glomerulosclerosis (b), and tubulointerstitial changes (c) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (■) compared with minor glomerular abnormalities (MGA) (square). *P < 0.05 vs MGA; daggerP < 0.01 vs MGA
###end p 31
###begin p 32
###xml 40 41 40 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 64 65 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 100 101 100 101 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 336 337 331 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 359 360 349 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
The scorings of glomerular cell number (a), glomerulosclerosis (b), and tubulointerstitial changes (c) in the biopsies. Glomerular cell count and glomerulosclerotic indexes except tubulointerstitial changes significantly increased in immunoglobulin A nephropathy (IgAN) (■) compared with minor glomerular abnormalities (MGA) (square). *P < 0.05 vs MGA; daggerP < 0.01 vs MGA
###end p 32
###begin title 33
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Expression of RAS components, TGF-beta, and alpha-SM actin in patients with MGA or IgAN
###end title 33
###begin p 34
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 766 767 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1001 1007 1001 1007 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1205 1206 1205 1206 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1248 1249 1248 1249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1464 1465 1464 1465 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1555 1560 1555 1560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 1562 1563 1562 1563 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1565 1566 1565 1566 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1568 1569 1568 1569 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1631 1634 1631 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1636 1637 1636 1637 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1672 1675 1672 1675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1677 1678 1677 1678 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1701 1704 1701 1704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1706 1707 1706 1707 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1788 1789 1788 1789 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1816 1817 1816 1817 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1850 1851 1850 1851 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1007 1867 1007 1867 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>) (original magnification &#215;200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (<bold>c</bold>). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (<italic>green</italic>; <bold>d</bold>, <bold>g</bold>, <bold>j</bold>) with either glomerular endothelial cells (GEC) marker CD31 (<italic>red</italic>; <bold>e</bold>), activated mesangial cells (MC) (<italic>red</italic>; <bold>h</bold>), or podocyte marker (<italic>red</italic>; <bold>k</bold>) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (<bold>f</bold>), weakly on activated MC (<bold>i</bold>), and only faintly on podocyte (<bold>l</bold>) in IgAN (&#215;400)</p>
###xml 1007 1867 1007 1867 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>) (original magnification &#215;200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (<bold>c</bold>). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (<italic>green</italic>; <bold>d</bold>, <bold>g</bold>, <bold>j</bold>) with either glomerular endothelial cells (GEC) marker CD31 (<italic>red</italic>; <bold>e</bold>), activated mesangial cells (MC) (<italic>red</italic>; <bold>h</bold>), or podocyte marker (<italic>red</italic>; <bold>k</bold>) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (<bold>f</bold>), weakly on activated MC (<bold>i</bold>), and only faintly on podocyte (<bold>l</bold>) in IgAN (&#215;400)</p></caption>
###xml 1867 1867 1867 1867 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig2_HTML" id="MO2"/>
###xml 1001 1867 1001 1867 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="35">Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>) (original magnification &#215;200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (<bold>c</bold>). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (<italic>green</italic>; <bold>d</bold>, <bold>g</bold>, <bold>j</bold>) with either glomerular endothelial cells (GEC) marker CD31 (<italic>red</italic>; <bold>e</bold>), activated mesangial cells (MC) (<italic>red</italic>; <bold>h</bold>), or podocyte marker (<italic>red</italic>; <bold>k</bold>) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (<bold>f</bold>), weakly on activated MC (<bold>i</bold>), and only faintly on podocyte (<bold>l</bold>) in IgAN (&#215;400)</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig2_HTML" id="MO2"/></fig>
###xml 105 113 <span type="species:ncbi:9606">patients</span>
###xml 343 346 <span type="species:ncbi:10116">rat</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 598 605 <span type="species:ncbi:9031">chicken</span>
###xml 666 671 <span type="species:ncbi:9606">human</span>
###xml 1153 1161 <span type="species:ncbi:9606">patients</span>
###xml 1342 1349 <span type="species:ncbi:9031">chicken</span>
###xml 1410 1415 <span type="species:ncbi:9606">human</span>
The glomerular localization of RAS components was studied by immunohistochemistry in renal biopsies from patients with either IgAN or MGA. Immunostaining of AGT was detected mainly in proximal tubules and weakly in GEC lining capillary walls in MGA specimens, as in normal tissues (Fig. 2a). This renal localization of AGT was consistent with rat renal localization of AGT, as previously described [33]. Of note, the staining level of AGT was enhanced in a typical endocapillary pattern, including changes of GEC and MC in IgAN patients (Fig. 2b). No positive immunostaining of AGT was seen when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody or when the primary antibody was omitted (Fig. 2c). The double immunostaining in IgAN showed that AGT was primarily detected on GEC, to a lesser extent on MC, and only faintly on podocytes, supporting the glomerular localization of AGT in an immunoperoxidase technique (Fig. 2d-l). Fig. 2Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (a) or immunoglobulin A nephropathy (IgAN) (b) (original magnification x200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (c). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (green; d, g, j) with either glomerular endothelial cells (GEC) marker CD31 (red; e), activated mesangial cells (MC) (red; h), or podocyte marker (red; k) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (f), weakly on activated MC (i), and only faintly on podocyte (l) in IgAN (x400)
###end p 34
###begin p 35
###xml 198 199 198 199 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 241 242 241 242 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 457 458 457 458 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 548 553 548 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 555 556 555 556 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 558 559 558 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 561 562 561 562 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 624 627 624 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 629 630 629 630 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 665 668 665 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 670 671 670 671 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 694 697 694 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 699 700 699 700 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 781 782 781 782 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 809 810 809 810 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 843 844 843 844 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 335 342 <span type="species:ncbi:9031">chicken</span>
###xml 403 408 <span type="species:ncbi:9606">human</span>
Glomerular expression of angiotensinogen (AGT) and its localization in the biopsies. Kidney sections were immunostained with anti-AGT antibody in patients with minor glomerular abnormalities (MGA) (a) or immunoglobulin A nephropathy (IgAN) (b) (original magnification x200). Positive immunostaining of AGT could not be detected when a chicken antibody against AGT, absorbed by preincubation with excess human purified AGT, was used as the primary antibody (c). To identify glomerular localization of AGT, double immunofluorescence staining of AGT (green; d, g, j) with either glomerular endothelial cells (GEC) marker CD31 (red; e), activated mesangial cells (MC) (red; h), or podocyte marker (red; k) in IgAN was performed. Merged images show that AGT clearly colocalized on GEC (f), weakly on activated MC (i), and only faintly on podocyte (l) in IgAN (x400)
###end p 35
###begin p 36
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 583 584 583 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 590 596 590 596 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 779 780 779 780 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 782 783 782 783 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 816 817 816 817 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 819 820 819 820 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 871 872 871 872 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 874 875 874 875 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 932 933 932 933 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 935 936 935 936 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 938 939 938 939 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 981 982 981 982 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 984 985 984 985 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 987 988 987 988 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 596 1020 596 1020 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37">Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (<bold>a</bold>, <bold>b</bold>), anti-angiotensin II antibody (<bold>c</bold>, <bold>d</bold>) or anti-angiotensin II type 1 receptor antibody (<bold>e</bold>, <bold>f</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) (original magnification, &#215;200)</p>
###xml 596 1020 596 1020 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37">Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (<bold>a</bold>, <bold>b</bold>), anti-angiotensin II antibody (<bold>c</bold>, <bold>d</bold>) or anti-angiotensin II type 1 receptor antibody (<bold>e</bold>, <bold>f</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) (original magnification, &#215;200)</p></caption>
###xml 1020 1020 1020 1020 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig3_HTML" id="MO3"/>
###xml 590 1020 590 1020 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="37">Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (<bold>a</bold>, <bold>b</bold>), anti-angiotensin II antibody (<bold>c</bold>, <bold>d</bold>) or anti-angiotensin II type 1 receptor antibody (<bold>e</bold>, <bold>f</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>) (original magnification, &#215;200)</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig3_HTML" id="MO3"/></fig>
###xml 210 218 <span type="species:ncbi:9606">patients</span>
###xml 271 279 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
###xml 880 888 <span type="species:ncbi:9606">patients</span>
ACE and ang II expression were examined by immunofluorescence, as specific staining was not detected by the immunoperoxidase technique. Faint immunofluorescence of ACE and ang II was observed in glomeruli from patients with MGA, as in normal tissues (Fig. 3a,c). In IgAN patients, staining for ACE tended to increase in an endocapillary pattern, but that of ang II was enhanced in GEC and MC of nephritic glomeruli (Fig. 3b,d). A similar staining level of AT1R was found in glomeruli, particularly MC, in specimens from patients with MGA or IgAN, and in control kidney tissues (Fig. 3e,f). Fig. 3Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (a, b), anti-angiotensin II antibody (c, d) or anti-angiotensin II type 1 receptor antibody (e, f) in patients with minor glomerular abnormalities (MGA) (a, c, e) or immunoglobulin A nephropathy (IgAN) (b, d, f) (original magnification, x200)
###end p 36
###begin p 37
###xml 183 184 183 184 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 186 187 186 187 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 220 221 220 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 223 224 223 224 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 275 276 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 278 279 278 279 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 336 337 336 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 339 340 339 340 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 342 343 342 343 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 385 386 385 386 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 388 389 388 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 391 392 391 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
Glomerular expression of components of the renin-angiotensin system (RAS) in the biopsies. Kidney sections were immunostained with either anti-angiotensin-converting enzyme antibody (a, b), anti-angiotensin II antibody (c, d) or anti-angiotensin II type 1 receptor antibody (e, f) in patients with minor glomerular abnormalities (MGA) (a, c, e) or immunoglobulin A nephropathy (IgAN) (b, d, f) (original magnification, x200)
###end p 37
###begin p 38
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 537 543 537 543 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 887 888 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 543 902 543 890 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (&#9633;) or immunoglobulin A nephropathy (IgAN) (&#9632;). Data are means &#177; standard deviation. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p>
###xml 543 902 543 890 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (&#9633;) or immunoglobulin A nephropathy (IgAN) (&#9632;). Data are means &#177; standard deviation. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></caption>
###xml 902 902 890 890 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig4_HTML" id="MO4"/>
###xml 537 902 537 890 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="39">Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (&#9633;) or immunoglobulin A nephropathy (IgAN) (&#9632;). Data are means &#177; standard deviation. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs MGA</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig4_HTML" id="MO4"/></fig>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
A semiquantitative analysis of glomerular staining for AGT, ACE, ang II, and AT1R revealed that the level of glomerular AGT (mean score 1.89) and ang II (mean score 2.09) but not ACE (mean score 0.96) was significantly enhanced in the IgAN group compared with the MGA group (mean scores for AGT, ang II, ACE 0.93, 1.00, 0.50, respectively) (P < 0.01) (Fig. 4). The expression level of AT1R tended to be lower, but not statistically significant, in patients with IgAN compared with the MGA group (mean score 1.63 in MGA vs 1.26 in IgAN). Fig. 4Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (square) or immunoglobulin A nephropathy (IgAN) (■). Data are means +/- standard deviation. daggerP < 0.01 vs MGA
###end p 38
###begin p 39
###xml 344 345 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 195 203 <span type="species:ncbi:9606">patients</span>
Semiquantitative assessment of immunostaining of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II (ang II) and ang II type 1 receptor (AT1R) in the kidney sections from patients with minor glomerular abnormalities (MGA) (square) or immunoglobulin A nephropathy (IgAN) (■). Data are means +/- standard deviation. daggerP < 0.01 vs MGA
###end p 39
###begin p 40
###xml 215 216 208 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 440 442 426 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 457 458 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 462 468 448 454 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 661 662 630 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 664 665 633 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 686 687 651 652 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 689 690 654 655 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 747 748 712 713 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 750 751 715 716 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 793 794 758 759 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 796 797 761 762 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 984 985 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 468 998 454 946 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Glomerular expression of transforming growth factor-&#946; (TGF-&#946;) and &#945;-smooth-muscle (&#945;-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-&#946; antibody (<bold>a</bold>, <bold>b</bold>) or &#945;-SM actin (<bold>c</bold>, <bold>d</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>) (original magnification &#215;200). Semiquantitative assessment of immunofluorescence staining of TGF-&#946; and &#945;-SM actin immunostaining in patients with MGA (&#9633;) or IgAN (&#9632;). &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01vs MGA</p>
###xml 468 998 454 946 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Glomerular expression of transforming growth factor-&#946; (TGF-&#946;) and &#945;-smooth-muscle (&#945;-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-&#946; antibody (<bold>a</bold>, <bold>b</bold>) or &#945;-SM actin (<bold>c</bold>, <bold>d</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>) (original magnification &#215;200). Semiquantitative assessment of immunofluorescence staining of TGF-&#946; and &#945;-SM actin immunostaining in patients with MGA (&#9633;) or IgAN (&#9632;). &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01vs MGA</p></caption>
###xml 998 998 946 946 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig5_HTML" id="MO5"/>
###xml 462 998 448 946 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="41">Glomerular expression of transforming growth factor-&#946; (TGF-&#946;) and &#945;-smooth-muscle (&#945;-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-&#946; antibody (<bold>a</bold>, <bold>b</bold>) or &#945;-SM actin (<bold>c</bold>, <bold>d</bold>) in patients with minor glomerular abnormalities (MGA) (<bold>a</bold>, <bold>c</bold>) or immunoglobulin A nephropathy (IgAN) (<bold>b</bold>, <bold>d</bold>) (original magnification &#215;200). Semiquantitative assessment of immunofluorescence staining of TGF-&#946; and &#945;-SM actin immunostaining in patients with MGA (&#9633;) or IgAN (&#9632;). &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01vs MGA</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig5_HTML" id="MO5"/></fig>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 695 703 <span type="species:ncbi:9606">patients</span>
###xml 938 946 <span type="species:ncbi:9606">patients</span>
The expression of TGF-beta and alpha-SM actin, potential factors associated with GN progression, was greatly enhanced in the expanded mesangial regions in patients with IgAN in contrast with patients with MGA (Fig. 5a-d). Semiquantitative analysis indicated that the levels of TGF-beta and alpha-SM actin expression were significantly higher in the IgAN group than in the MGA group (mean score 0.50 and 0.63 in MGA vs 1.91 and 1.91 in IgAN; P < 0.01) (Fig. 5e). Fig. 5Glomerular expression of transforming growth factor-beta (TGF-beta) and alpha-smooth-muscle (alpha-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-beta antibody (a, b) or alpha-SM actin (c, d) in patients with minor glomerular abnormalities (MGA) (a, c) or immunoglobulin A nephropathy (IgAN) (b, d) (original magnification x200). Semiquantitative assessment of immunofluorescence staining of TGF-beta and alpha-SM actin immunostaining in patients with MGA (square) or IgAN (■). daggerP < 0.01vs MGA
###end p 40
###begin p 41
###xml 193 194 176 177 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 196 197 179 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 218 219 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 221 222 200 201 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 279 280 258 259 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 282 283 261 262 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 325 326 304 305 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 328 329 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 516 517 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
Glomerular expression of transforming growth factor-beta (TGF-beta) and alpha-smooth-muscle (alpha-SM) actin in biopsies. Kidney sections were immunostained with either anti-TGF-beta antibody (a, b) or alpha-SM actin (c, d) in patients with minor glomerular abnormalities (MGA) (a, c) or immunoglobulin A nephropathy (IgAN) (b, d) (original magnification x200). Semiquantitative assessment of immunofluorescence staining of TGF-beta and alpha-SM actin immunostaining in patients with MGA (square) or IgAN (■). daggerP < 0.01vs MGA
###end p 41
###begin title 42
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Correlation of RAS components with pathologic changes in patients with MGA or IgAN
###end title 42
###begin p 43
###xml 334 335 327 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 407 408 400 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 418 420 411 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 436 437 429 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 451 452 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 462 464 452 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 480 481 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 501 502 487 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 512 514 498 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 530 531 516 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 559 560 545 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 570 572 556 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 588 589 574 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 603 604 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 614 616 600 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 632 633 618 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 654 655 640 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 665 667 651 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 682 683 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 787 788 770 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 798 800 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 816 817 799 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 837 838 816 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 848 850 827 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 866 867 845 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 884 885 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 895 897 874 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 912 913 891 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 927 928 906 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 937 939 916 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 955 956 934 935 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 977 978 956 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 988 990 967 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1005 1006 984 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 1212 1213 1184 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1223 1225 1195 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1241 1242 1213 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 1246 1252 1218 1224 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 1356 1357 1328 1329 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1412 1413 1378 1379 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1462 1463 1420 1421 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1512 1513 1470 1471 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 1555 1556 1513 1514 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 1580 1581 1538 1539 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 1605 1606 1560 1561 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 1636 1637 1587 1588 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 1664 1665 1615 1616 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 1689 1690 1640 1641 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 1717 1718 1668 1669 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1754 1755 1698 1699 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 1871 1873 1815 1817 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1946 1947 1890 1891 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1957 1959 1901 1903 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1980 1981 1921 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1991 1993 1932 1934 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2017 2018 1958 1959 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2028 2030 1969 1971 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2051 2052 1992 1993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2062 2064 2003 2005 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2092 2093 2033 2034 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2104 2105 2045 2046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2167 2168 2105 2106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2179 2180 2117 2118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2207 2208 2141 2142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2218 2220 2152 2154 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2244 2245 2178 2179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2255 2257 2189 2191 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2277 2278 2211 2212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2288 2290 2222 2224 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2318 2319 2252 2253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2329 2331 2263 2265 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 2419 2420 2346 2347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 2430 2432 2357 2359 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1252 2441 1224 2368 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (<bold>a</bold>), AGT and transforming growth factor-&#946; (TGF-&#946;) (<bold>b</bold>), AGT and &#945;-smooth-muscle (&#945;-SM) actin (<bold>c</bold>), AGT and glomerular cell number (cell number) (<bold>d</bold>), AGT and glomerulosclerosis (GS) score (<bold>e</bold>), AGT and proteinuria (<bold>f</bold>), ang II and TGF-&#946; (<bold>g</bold>), ang II and &#945;-SM actin (<bold>h</bold>), ang II and cell number (<bold>i</bold>), ang II and GS score (<bold>j</bold>), ang II and proteinuria (<bold>k</bold>), and TGF-&#946; and &#945;-SM actin (<bold>l</bold>) in patients with minor glomerular abnormalities (MGA) (&#9675;) or immunoglobulin A nephropathy (IgAN) (&#8226;) (correlation;<italic> P</italic> value) The levels of AGT positively correlate with the level of ang II (<italic>r</italic>&#8201;=&#8201;+0.711;<italic> P</italic>&#8201;&lt;&#8201;0.001), TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.723;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.542;<italic> P</italic>&#8201;&lt;&#8201;0.005), GS score (<italic>r</italic>&#8201;=&#8201;+0.768;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.436; <italic>P</italic>&#8201;&lt;&#8201;0.05). Ang II is also positively correlated with TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.782; <italic>P</italic>&#8201;&lt;&#8201;0.001), &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.640;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.441;<italic> P</italic>&#8201;&lt;&#8201;0.05), GS score (<italic>r</italic>&#8201;=&#8201;+0.826;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.364;<italic> P</italic>&#8201;&lt;&#8201;0.05). The levels of TGF-&#946; positively correlate with the level of &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.625;<italic> P</italic>&#8201;&lt;&#8201;0.001)</p>
###xml 1252 2441 1224 2368 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (<bold>a</bold>), AGT and transforming growth factor-&#946; (TGF-&#946;) (<bold>b</bold>), AGT and &#945;-smooth-muscle (&#945;-SM) actin (<bold>c</bold>), AGT and glomerular cell number (cell number) (<bold>d</bold>), AGT and glomerulosclerosis (GS) score (<bold>e</bold>), AGT and proteinuria (<bold>f</bold>), ang II and TGF-&#946; (<bold>g</bold>), ang II and &#945;-SM actin (<bold>h</bold>), ang II and cell number (<bold>i</bold>), ang II and GS score (<bold>j</bold>), ang II and proteinuria (<bold>k</bold>), and TGF-&#946; and &#945;-SM actin (<bold>l</bold>) in patients with minor glomerular abnormalities (MGA) (&#9675;) or immunoglobulin A nephropathy (IgAN) (&#8226;) (correlation;<italic> P</italic> value) The levels of AGT positively correlate with the level of ang II (<italic>r</italic>&#8201;=&#8201;+0.711;<italic> P</italic>&#8201;&lt;&#8201;0.001), TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.723;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.542;<italic> P</italic>&#8201;&lt;&#8201;0.005), GS score (<italic>r</italic>&#8201;=&#8201;+0.768;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.436; <italic>P</italic>&#8201;&lt;&#8201;0.05). Ang II is also positively correlated with TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.782; <italic>P</italic>&#8201;&lt;&#8201;0.001), &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.640;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.441;<italic> P</italic>&#8201;&lt;&#8201;0.05), GS score (<italic>r</italic>&#8201;=&#8201;+0.826;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.364;<italic> P</italic>&#8201;&lt;&#8201;0.05). The levels of TGF-&#946; positively correlate with the level of &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.625;<italic> P</italic>&#8201;&lt;&#8201;0.001)</p></caption>
###xml 2441 2441 2368 2368 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig6_HTML" id="MO6"/>
###xml 1246 2441 1218 2368 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="44">Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (<bold>a</bold>), AGT and transforming growth factor-&#946; (TGF-&#946;) (<bold>b</bold>), AGT and &#945;-smooth-muscle (&#945;-SM) actin (<bold>c</bold>), AGT and glomerular cell number (cell number) (<bold>d</bold>), AGT and glomerulosclerosis (GS) score (<bold>e</bold>), AGT and proteinuria (<bold>f</bold>), ang II and TGF-&#946; (<bold>g</bold>), ang II and &#945;-SM actin (<bold>h</bold>), ang II and cell number (<bold>i</bold>), ang II and GS score (<bold>j</bold>), ang II and proteinuria (<bold>k</bold>), and TGF-&#946; and &#945;-SM actin (<bold>l</bold>) in patients with minor glomerular abnormalities (MGA) (&#9675;) or immunoglobulin A nephropathy (IgAN) (&#8226;) (correlation;<italic> P</italic> value) The levels of AGT positively correlate with the level of ang II (<italic>r</italic>&#8201;=&#8201;+0.711;<italic> P</italic>&#8201;&lt;&#8201;0.001), TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.723;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.542;<italic> P</italic>&#8201;&lt;&#8201;0.005), GS score (<italic>r</italic>&#8201;=&#8201;+0.768;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.436; <italic>P</italic>&#8201;&lt;&#8201;0.05). Ang II is also positively correlated with TGF-&#946; (<italic>r</italic>&#8201;=&#8201;+0.782; <italic>P</italic>&#8201;&lt;&#8201;0.001), &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.640;<italic> P</italic>&#8201;&lt;&#8201;0.001), cell number (<italic>r</italic>&#8201;=&#8201;+0.441;<italic> P</italic>&#8201;&lt;&#8201;0.05), GS score (<italic>r</italic>&#8201;=&#8201;+0.826;<italic> P</italic>&#8201;&lt;&#8201;0.001), and proteinuria (<italic>r</italic>&#8201;=&#8201;+0.364;<italic> P</italic>&#8201;&lt;&#8201;0.05). The levels of TGF-&#946; positively correlate with the level of &#945;-SM actin (<italic>r</italic>&#8201;=&#8201;+0.625;<italic> P</italic>&#8201;&lt;&#8201;0.001)</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig6_HTML" id="MO6"/></fig>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
###xml 1760 1768 <span type="species:ncbi:9606">patients</span>
Possible relationships between glomerular RAS activation and injury in diseased kidney were investigated to examine the correlations between the expression of RAS components, ang II-inducible factors, TGF-beta and alpha-SM actin histologic findings, and urinary findings (proteinuria and hematuria) in patients with MGA or IgAN (Fig. 6). The glomerular AGT expression was positively correlated with ang II (r = +0.711, P < 0.001) (Fig. 6a), TGF-beta (r = +0.723, P < 0.001) (Fig. 6b), alpha-SM actin (r = +0.565, P < 0.005) (Fig. 6c), glomerular cell number (r = +0.542, P < 0.005) (Fig. 6d), GS score (r = +0.768, P < 0.001) (Fig. 6e), and proteinuria (r = +0.436, P < 0.05) (Fig. 6f). Similarly, glomerular ang II level showed a significant positive correlation with that of TGF-beta (r = +0.782, P < 0.001) (Fig. 6g), alpha-SM actin (r = +0.640, P < 0.001) (Fig. 6h), cell number (r = +0.441, P < 0.05) (Fig. 6i), GS score (r = 0.826, P < 0.001) (Fig. 6j), and proteinuria (r = +0.364, P < 0.05) (Fig. 6k). However, neither AGT nor ang II showed a significant correlation with expression of ACE, AT1R, and hematuria index. Finally, a positive correlation was demonstrated between TGF-beta and alpha-SM actin (r = +0.625, P < 0.001) (Fig. 6l). Fig. 6Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (a), AGT and transforming growth factor-beta (TGF-beta) (b), AGT and alpha-smooth-muscle (alpha-SM) actin (c), AGT and glomerular cell number (cell number) (d), AGT and glomerulosclerosis (GS) score (e), AGT and proteinuria (f), ang II and TGF-beta (g), ang II and alpha-SM actin (h), ang II and cell number (i), ang II and GS score (j), ang II and proteinuria (k), and TGF-beta and alpha-SM actin (l) in patients with minor glomerular abnormalities (MGA) (o) or immunoglobulin A nephropathy (IgAN) (*) (correlation; P value) The levels of AGT positively correlate with the level of ang II (r = +0.711; P < 0.001), TGF-beta (r = +0.723; P < 0.001), cell number (r = +0.542; P < 0.005), GS score (r = +0.768; P < 0.001), and proteinuria (r = +0.436; P < 0.05). Ang II is also positively correlated with TGF-beta (r = +0.782; P < 0.001), alpha-SM actin (r = +0.640; P < 0.001), cell number (r = +0.441; P < 0.05), GS score (r = +0.826; P < 0.001), and proteinuria (r = +0.364; P < 0.05). The levels of TGF-beta positively correlate with the level of alpha-SM actin (r = +0.625; P < 0.001)
###end p 43
###begin p 44
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 160 161 154 155 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 210 211 196 197 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 260 261 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 303 304 289 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 328 329 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 353 354 336 337 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 384 385 363 364 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 412 413 391 392 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 437 438 416 417 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 465 466 444 445 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 502 503 474 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 619 621 591 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 694 695 666 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 705 707 677 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 728 729 697 698 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 739 741 708 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 765 766 734 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 776 778 745 747 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 799 800 768 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 810 812 779 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 840 841 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 852 853 821 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 915 916 881 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 927 928 893 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 955 956 917 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 966 968 928 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 992 993 954 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1003 1005 965 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1025 1026 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1036 1038 998 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1066 1067 1028 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1077 1079 1039 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 1167 1168 1122 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1178 1180 1133 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> P</italic>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
Plots of correlations between the staining levels of angiotensinogen (AGT) and angiotensin II (ang II) (a), AGT and transforming growth factor-beta (TGF-beta) (b), AGT and alpha-smooth-muscle (alpha-SM) actin (c), AGT and glomerular cell number (cell number) (d), AGT and glomerulosclerosis (GS) score (e), AGT and proteinuria (f), ang II and TGF-beta (g), ang II and alpha-SM actin (h), ang II and cell number (i), ang II and GS score (j), ang II and proteinuria (k), and TGF-beta and alpha-SM actin (l) in patients with minor glomerular abnormalities (MGA) (o) or immunoglobulin A nephropathy (IgAN) (*) (correlation; P value) The levels of AGT positively correlate with the level of ang II (r = +0.711; P < 0.001), TGF-beta (r = +0.723; P < 0.001), cell number (r = +0.542; P < 0.005), GS score (r = +0.768; P < 0.001), and proteinuria (r = +0.436; P < 0.05). Ang II is also positively correlated with TGF-beta (r = +0.782; P < 0.001), alpha-SM actin (r = +0.640; P < 0.001), cell number (r = +0.441; P < 0.05), GS score (r = +0.826; P < 0.001), and proteinuria (r = +0.364; P < 0.05). The levels of TGF-beta positively correlate with the level of alpha-SM actin (r = +0.625; P < 0.001)
###end p 44
###begin title 45
###xml 55 60 <span type="species:ncbi:9606">human</span>
Effect of ang II on the AGT mRNA and protein levels by human GEC
###end title 45
###begin p 46
###xml 160 162 160 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 520 523 520 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 530 532 530 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 550 551 550 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 640 642 640 642 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 796 797 796 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 945 948 945 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;11</sup>
###xml 957 959 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 968 969 968 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig8" ref-type="fig">8</xref>
###xml 973 979 973 979 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 1177 1179 1177 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 1306 1307 1306 1307 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1357 1358 1355 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1376 1377 1369 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1540 1541 1533 1534 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1547 1553 1540 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> graph</italic>
###xml 1625 1626 1616 1617 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1644 1645 1630 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 979 1663 979 1649 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (<bold>a</bold>). Values are means &#177; standard deviation (SD). *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (<bold>b</bold>). The<italic> graph</italic> represents the mean &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs control</p>
###xml 979 1663 979 1649 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (<bold>a</bold>). Values are means &#177; standard deviation (SD). *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (<bold>b</bold>). The<italic> graph</italic> represents the mean &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs control</p></caption>
###xml 1663 1663 1649 1649 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig7_HTML" id="MO7"/>
###xml 973 1663 973 1649 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="47">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (<bold>a</bold>). Values are means &#177; standard deviation (SD). *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (<bold>b</bold>). The<italic> graph</italic> represents the mean &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 and &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs control</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig7_HTML" id="MO7"/></fig>
###xml 1663 1669 1649 1655 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;8</label>
###xml 1841 1843 1827 1829 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 1956 1957 1939 1940 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2128 2134 2108 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> graph</italic>
###xml 2232 2233 2205 2206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 2383 2384 2356 2357 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 2386 2387 2359 2360 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2456 2457 2427 2428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1669 2475 1655 2446 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and &#946;-actin (<bold>a</bold>). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60&#160;kD. Data for AGT protein levels were normalized by &#946;-actin protein levels. The<italic> graph</italic> represents the mean &#177; standard deviation (SD) of at least three independent experiments. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in <bold>a</bold> (<bold>b</bold>). Data are means &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs control</p>
###xml 1669 2475 1655 2446 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="48">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and &#946;-actin (<bold>a</bold>). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60&#160;kD. Data for AGT protein levels were normalized by &#946;-actin protein levels. The<italic> graph</italic> represents the mean &#177; standard deviation (SD) of at least three independent experiments. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in <bold>a</bold> (<bold>b</bold>). Data are means &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs control</p></caption>
###xml 2475 2475 2446 2446 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="467_2008_801_Fig8_HTML" id="MO8"/>
###xml 1663 2475 1649 2446 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig8"><label>Fig.&#160;8</label><caption><p textid="48">Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10<sup>&#8722;7</sup>&#160;M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and &#946;-actin (<bold>a</bold>). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60&#160;kD. Data for AGT protein levels were normalized by &#946;-actin protein levels. The<italic> graph</italic> represents the mean &#177; standard deviation (SD) of at least three independent experiments. &#8224;<italic>P</italic>&#8201;&lt;&#8201;0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in <bold>a</bold> (<bold>b</bold>). Data are means &#177; SD of at least three independent experiments. *<italic>P</italic>&#8201;&lt;&#8201;0.05 vs control</p></caption><graphic position="anchor" xlink:href="467_2008_801_Fig8_HTML" id="MO8"/></fig>
###xml 131 136 <span type="species:ncbi:9606">human</span>
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 878 883 <span type="species:ncbi:9606">human</span>
###xml 1103 1108 <span type="species:ncbi:9606">human</span>
###xml 1145 1150 <span type="species:ncbi:9606">Human</span>
###xml 1396 1401 <span type="species:ncbi:9606">Human</span>
###xml 1767 1772 <span type="species:ncbi:9606">human</span>
###xml 1809 1814 <span type="species:ncbi:9606">Human</span>
###xml 2252 2257 <span type="species:ncbi:9606">Human</span>
The regulation of AGT expression by GEC and a possible role of GEC-AGT in disease progression of IgAN were examined using cultured human GEC. The addition of 10-7 M ang II rapidly induced AGT mRNA expression of quiescent human GEC after stimulation for 1 h. This increase peaked at 3 h, with a sevenfold increase, and then gradually decreased during the course of the experiment (Fig. 7a). When the response of AGT transcript to ang II dose was investigated after incubation for 3 h, a dose-dependent increase between 10-11 and 10-7 M was seen (Fig. 7b). Western blot analysis revealed a time-dependent increase of AGT protein product to 10-7 M ang II stimulation. The increased expression of AGT protein followed the increase of AGT mRNA by GEC and peaked at 12 and 24 h after stimulation (Fig. 8a). Consistent with the results of RT-PCR analysis, a dose-dependent increase of human GEC-AGT protein to ang II stimulation was observed between 10-11 M and 10-7 M (Fig. 8b). Fig. 7Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10-7 M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (a). Values are means +/- standard deviation (SD). *P < 0.05 and daggerP < 0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (b). The graph represents the mean +/- SD of at least three independent experiments. *P < 0.05 and daggerP < 0.01 vs controlFig. 8Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10-7 M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and beta-actin (a). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60 kD. Data for AGT protein levels were normalized by beta-actin protein levels. The graph represents the mean +/- standard deviation (SD) of at least three independent experiments. daggerP < 0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in a (b). Data are means +/- SD of at least three independent experiments. *P < 0.05 vs control
###end p 46
###begin p 47
###xml 198 200 198 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 327 328 327 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 378 379 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 397 398 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 561 562 554 555 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 568 574 561 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> graph</italic>
###xml 646 647 637 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 665 666 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 166 171 <span type="species:ncbi:9606">Human</span>
###xml 417 422 <span type="species:ncbi:9606">Human</span>
Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) messenger ribonucleic acid (mRNA) by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10-7 M ang II for the indicated time, extracted, and analyzed for AGT mRNA levels by real-time polymerase chain reaction (RT-PCR) (a). Values are means +/- standard deviation (SD). *P < 0.05 and daggerP < 0.01 vs time 0. Human GEC were incubated for 3 h with vehicle control or with indicated doses of ang II, extracted, and analyzed for AGT mRNA levels by RT-PCR (b). The graph represents the mean +/- SD of at least three independent experiments. *P < 0.05 and daggerP < 0.01 vs control
###end p 47
###begin p 48
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;7</sup>
###xml 287 288 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 459 465 453 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> graph</italic>
###xml 563 564 550 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 714 715 701 702 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 717 718 704 705 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 787 788 772 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 98 103 <span type="species:ncbi:9606">human</span>
###xml 140 145 <span type="species:ncbi:9606">Human</span>
###xml 583 588 <span type="species:ncbi:9606">Human</span>
Effects of angiotensin II (ang II) on the expression of angiotensinogen (AGT) protein by cultured human glomerular endothelial cells (GEC). Human GEC were incubated with 10-7 M ang II for the indicated time, extracted, and then subjected to Western blot analysis for AGT and beta-actin (a). Western blot analysis demonstrated two specific immunoreactive bands between 50 and 60 kD. Data for AGT protein levels were normalized by beta-actin protein levels. The graph represents the mean +/- standard deviation (SD) of at least three independent experiments. daggerP < 0.01 vs time 0. Human GEC were incubated for 12 h with vehicle control or with indicated doses of ang II, extracted, and analyzed, as described in a (b). Data are means +/- SD of at least three independent experiments. *P < 0.05 vs control
###end p 48
###begin title 49
Discussion
###end title 49
###begin p 50
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 321 322 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 324 325 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 470 475 <span type="species:ncbi:9606">human</span>
###xml 507 515 <span type="species:ncbi:9606">patients</span>
Enhanced intrarenal RAS has been implicated in the development of hypertension and the progression of chronic renal diseases, including IgAN [1, 2, 17]. Ang II, the major effector molecule of the RAS cascade, is a key mediator of glomerular hypertension as well as glomerular sclerosis through the induction of TGF-beta [5, 6]. However, glomerular expression of RAS components and their association with local RAS activity and injury has not been extensively studied in human subjects, especially pediatric patients with IgAN.
###end p 50
###begin p 51
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 387 389 387 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
In this study, we demonstrated for the first time that both glomerular expression of AGT protein, a sole substrate for RAS cascade, and ang II were strikingly increased with GEC and MC in nephritic glomeruli of pediatric IgAN. As it is already known that ang II is locally produced within the glomerulus and RAS is present in glomerular cell types such as GEC, MC, and podocyte [19, 20, 34], the increased expression of ang II seen in pediatric IgAN most likely reflects enhanced glomerular RAS activation under this disease setting.
###end p 51
###begin p 52
###xml 459 461 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 463 465 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 467 469 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 471 473 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 533 537 526 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> AGT</italic>
###xml 542 546 535 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> ACE</italic>
###xml 580 585 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> AT1R</italic>
###xml 751 753 744 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 897 902 890 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> AT1R</italic>
###xml 1490 1492 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1597 1599 1590 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 1733 1735 1726 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1737 1739 1730 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1741 1743 1734 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 2078 2080 2071 2073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 2081 2083 2074 2076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 2085 2087 2078 2080 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 1148 1156 <span type="species:ncbi:9606">patients</span>
###xml 1891 1894 <span type="species:ncbi:10116">rat</span>
We also demonstrated that there was a positive correlation between levels of glomerular AGT, ang II, and ang II-inducible factors (TGF-beta and alpha-SM actin) and glomerular injury (cell proliferation and ECM accumulation), suggesting that the activated glomerular RAS cascade contributes to the development and progression of glomerular injury in pediatric IgAN. There are several studies investigating glomerular gene expression of RAS components in IgAN [17, 24, 35, 36]. Most studies have shown an increased expression of renin, AGT, and ACE genes and decreased expression of AT1R gene in nephritic glomeruli of IgAN. Furthermore, it has been shown that a negative feedback loop exists between ang II and its receptor, AT1R, in glomerular cells [36]. Therefore, if there was a proportional increase in ang II as a result of increased upstream components of RAS, a proportional deactivation of AT1R expression in IgAN would be expected. Here, we found a significantly greater expression of glomerular AGT protein and ang II peptides and a tendency for higher ACE protein levels and lower AT1R protein levels in pediatric IgAN compared with MGA patients, indicating that the glomerular AGT level may directly regulate the ang II activity under the coordination of ACE and AT1R expression and other ang II-producible enzyme activity. Various enzymes, including cathepsin and chymase, are involved in the RAS besides renin and ACE, which are classical enzyme synthesizing ang II from AGT [37]. Indeed, approximately 40% of the ang II found in the kidney is generated by ACE-independent pathways [38]. In any case, local levels of renin and ACE are not related to the synthesis of angII in situations where AGT levels are very high [18, 20, 21]. Thus, the quantity of AGT might well be the most important element for the level of ang II production. Indeed, recent experimental studies using rat models of nephropathy indicated that enhanced intrarenal AGT expression is linked to the increased level of ang II production and contributes to the development of glomerular injury [20-22, 39].
###end p 52
###begin p 53
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 100 101 100 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 200 201 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 326 327 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 506 508 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
###xml 509 511 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 810 812 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 192 195 <span type="species:ncbi:10116">rat</span>
###xml 544 549 <span type="species:ncbi:9606">human</span>
We previously disclosed the mechanisms and the role of ang II-induced ECM deposition through MC [5, 6]. Ang II stimulates ECM synthesis through he induction of TGF-beta expression in cultured rat MC [5] and affects the plasminogen activator/plasminogen activator inhibitor-1 system to result in accelerated deposition of ECM [6], which indicates that ang II can act as a potent fibrotic molecule independent of its effects on blood pressure. Ang II can also induce MC activation (alpha-SM actin positive) [39-42]. In addition, experimental and human studies have shown that the degree of mesangial cellularity is associated with a high sensitivity to beneficial effects of ACEi and ARB on glomerular structure and proteinuria, suggesting that the glomerular ang II level may contribute to proliferation of MC [43]. Thus, our findings obtained here that the level of glomerular ang II is associated with the levels of TGF-beta and alpha-SM actin expression as well as glomerular injury characterized by cell proliferation and ECM accumulation are consistent with the recent view of ang II action.
###end p 53
###begin p 54
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">46</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">48</xref>
###xml 637 639 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 418 421 <span type="species:ncbi:10116">rat</span>
###xml 724 732 <span type="species:ncbi:9606">patients</span>
###xml 1147 1152 <span type="species:ncbi:9606">human</span>
GEC damage and dysfunction are early features of many types of GN [44, 45]. Injury to GEC induces the secretion of various mediators, such as vasoactive substances, cytokines, and growth factors critical in the regulation of glomerular capillary tone and glomerular remodeling [19, 46-48]. Lee et al. demonstrated that GEC injury results in increased AGT and TGF-beta mRNA by GEC and MC in the subtotal nephrectomized rat model, suggesting that activated or injured endothelial cells synthesize AGT, triggering a cascade of ang II, TGF-beta, and ECM protein gene expression with resultant development of the glomerular sclerotic lesion [19]. Here we provide in vivo data showing a striking increase of GEC-AGT and ang II in patients with IgAN as well as in vitro data indicating the potential of GEC to synthesize AGT protein and stimulatory effects of ang II on GEC-AGT expression. Taken together, it seems likely that GEC plays a crucial role in the activation of local RAS, and self-amplifying properties of ang II production in GEC are associated with the glomerular hemodynamic changes and the development of progressive glomerular injury in human GN.
###end p 54
###begin p 55
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 590 592 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">49</xref>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
In general, RAS inhibitors are commonly used by chronic IgAN patients with hypertension or those with heavy proteinuria or initial impairment of renal function. We should stress that glomerular RAS activation could occur in pediatric IgAN without heavy proteinuria, hypertension, and renal impairment. IgAN patients in this study had a short-term observation period from onset to time of renal biopsy, renal lesions, characterized with mesangial proliferative changes, low-grade interstitial fibrosis, and tubular atrophy, indicating that they were diagnosed at an early stage of IgAN [14, 49]. Thus, considering the accumulating evidence that ang II plays a critical role in MC activation as well as glomerular hemodynamic changes and development of glomerulosclerosis, early treatment with ACEi and/or ARB in pediatric IgAN, even in the absence of hypertension and/or severe proteinuria, is reasonable for preventing progression in IgAN.
###end p 55
###begin p 56
###xml 514 522 <span type="species:ncbi:9606">patients</span>
###xml 616 624 <span type="species:ncbi:9606">patients</span>
In conclusion, our study showed that activated glomerular AGT expression is likely to be involved in local RAS activation, leading to enhanced local ang II production, in pediatric IgAN with normal blood pressure and normal renal function and, thereby, may trigger a dangerous RAS cascade resulting in overproduction of TGF-beta and progression of glomerular injury. Moreover, a self-amplification loop of GEC-AGT production with ang II stimulation seems to drive the further injury of nephritic glomeruli in IgAN patients. These data provide a rationale for early intervention with RAS inhibitors in pediatric IgAN patients even in the absence of hypertension and/or impairment of renal function to prevent progression of glomerular injury.
###end p 56
###begin p 57
###xml 196 202 <span type="species:ncbi:9986">rabbit</span>
This work was supported by grants from the Japanese Ministry of Welfare (16591035, 18591189). We thank Dr. Hiroshi Kawachi and Dr. Fujio Shimizu (Niigata University, Niigata, Japan) for providing rabbit anti-TGF-beta antibody. We also thank Dr. Toshiaki Sano and Mrs. Naomi Okamoto for their excellent technical assistance. Parts of this work were published in abstract form at the 39th Annual Meeting of the American Society of Nephrology, 14-19 November 2006.
###end p 57
###begin p 58
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 58
###begin title 59
References
###end title 59
###begin article-title 60
###xml 138 141 <span type="species:ncbi:10116">rat</span>
Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat
###end article-title 60
###begin article-title 61
Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade
###end article-title 61
###begin article-title 62
###xml 80 83 <span type="species:ncbi:10116">rat</span>
Nonproportional changes in plasma renin concentration, renal renin content, and rat renin messenger RNA
###end article-title 62
###begin article-title 63
###xml 25 30 <span type="species:ncbi:9606">human</span>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Renin gene expression in human kidney biopsies from patients with glomerulonephritis or graft rejection
###end article-title 63
###begin article-title 64
###xml 132 135 <span type="species:ncbi:10116">rat</span>
Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
###end article-title 64
###begin article-title 65
###xml 68 71 <span type="species:ncbi:10116">rat</span>
Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
###end article-title 65
###begin article-title 66
Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts
###end article-title 66
###begin article-title 67
Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis
###end article-title 67
###begin article-title 68
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy
###end article-title 68
###begin article-title 69
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy
###end article-title 69
###begin article-title 70
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
###end article-title 70
###begin article-title 71
Factors predicting progression of IgA nephropathies
###end article-title 71
###begin article-title 72
A retrospective analysis of the natural history of primary IgA nephropathy worldwide
###end article-title 72
###begin article-title 73
###xml 40 48 <span type="species:ncbi:9606">children</span>
Mesangial changes in IgA nephropathy in children
###end article-title 73
###begin article-title 74
Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy
###end article-title 74
###begin article-title 75
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy
###end article-title 75
###begin article-title 76
Precocious activation of genes of the renin-angiotensin system and the fibrogenic cascade in IgA glomerulonephritis
###end article-title 76
###begin article-title 77
Yong scholars award lecture: intratubular angiotensinogen in hypertension and kidney diseases
###end article-title 77
###begin article-title 78
###xml 62 65 <span type="species:ncbi:10116">rat</span>
Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney
###end article-title 78
###begin article-title 79
###xml 74 77 <span type="species:ncbi:10116">rat</span>
A novel mechanism for angiotensin II formation in streptozotocin-diabetic rat glomeruli
###end article-title 79
###begin article-title 80
###xml 100 104 <span type="species:ncbi:10116">rats</span>
Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats
###end article-title 80
###begin article-title 81
Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor-beta1 expression in acute ureteral obstruction
###end article-title 81
###begin article-title 82
Tissue-specific expression of renin-angiotensin system components in IgA nephropathy
###end article-title 82
###begin article-title 83
###xml 59 64 <span type="species:ncbi:9606">human</span>
Expression of b1-integrins on activated mesangial cells in human glomerulonephritis
###end article-title 83
###begin article-title 84
Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy
###end article-title 84
###begin article-title 85
###xml 150 153 <span type="species:ncbi:10116">rat</span>
Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrests progressive mesangioproliferative glomerulonephritis in the rat
###end article-title 85
###begin article-title 86
###xml 55 60 <span type="species:ncbi:9606">human</span>
Enhanced expression of complement C5a receptor mRNA in human diseased kidney assessed by in situ hybridization
###end article-title 86
###begin article-title 87
###xml 18 23 <span type="species:ncbi:9606">human</span>
Quantification of human angiotensinogen by a novel sandwich ELISA
###end article-title 87
###begin article-title 88
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 120 125 <span type="species:ncbi:9606">human</span>
Expression of adhesion molecules by cultured human glomerular endothelial cells in response to cytokines: comparison to human umbilical vein and dermal microvascular endothelial cells
###end article-title 88
###begin article-title 89
###xml 27 32 <span type="species:ncbi:9606">human</span>
Role of N-glycosylation in human angiotensinogen
###end article-title 89
###begin article-title 90
###xml 123 128 <span type="species:ncbi:9606">human</span>
Local and systemic impact of transcriptional up-regulation of 11b-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity
###end article-title 90
###begin article-title 91
Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension
###end article-title 91
###begin article-title 92
###xml 57 62 <span type="species:ncbi:9606">human</span>
Functional expression of the renin-angiotensin system in human podocytes
###end article-title 92
###begin article-title 93
###xml 51 56 <span type="species:ncbi:9606">human</span>
Gene expression of the renin-angiotensin system in human kidney
###end article-title 93
###begin article-title 94
Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1
###end article-title 94
###begin article-title 95
The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease
###end article-title 95
###begin article-title 96
Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition
###end article-title 96
###begin article-title 97
Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis
###end article-title 97
###begin article-title 98
###xml 46 49 <span type="species:ncbi:10116">rat</span>
Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis. alpha-smooth muscle actin is a marker of mesangial cell proliferation
###end article-title 98
###begin article-title 99
Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth
###end article-title 99
###begin article-title 100
Renal injury from angiotensin II-mediated hypertension
###end article-title 100
###begin article-title 101
Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis
###end article-title 101
###begin article-title 102
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Elevation of von Willebrand factor levels in patients with IgA nephropathy: effect of ACE inhibition
###end article-title 102
###begin article-title 103
FB21, a monoclonal antibody that reacts with a sialic-acid-dependent carbohydrate epitope, is a marker for glomerular endothelial cell injury
###end article-title 103
###begin article-title 104
Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney
###end article-title 104
###begin article-title 105
###xml 41 44 <span type="species:ncbi:10116">rat</span>
Angiotensin II is mitogenic for cultured rat glomerular endothelial cells
###end article-title 105
###begin article-title 106
###xml 25 30 <span type="species:ncbi:9606">human</span>
AT1 and AT2 receptors in human glomerular endothelial cells at different passages
###end article-title 106
###begin article-title 107
###xml 28 36 <span type="species:ncbi:9606">children</span>
IgA nephropathy in Japanese children and adults: a comparative study of clinicopathological features
###end article-title 107

